| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;42:985.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
From the Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan.
Correspondence to Tomohiro Osanai, MD, Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562 Japan. E-mail osanait{at}cc.hirosaki-u.ac.jp
We demonstrated recently that plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, are increased by high salt intake concomitantly with a decrease in plasma levels of NO in human hypertension. We investigated the effect of shear stress on ADMA release in 2 types of cells: transformed human umbilical vein endothelial cells (HUVECs; cell line ECV-304) and HUVECs. Exposure of ECV-304 cells and HUVECs to shear stress with the use of a cone-plate viscometer enhanced gene expression of protein arginine methyltransferase (PRMT-1), ADMA synthase. In HUVECs, the ratio of PRMT-1 to glyceraldehyde 3-phosphate dehydrogenase mRNA was increased by 2-fold by a shear stress of
15 dyne/cm2. A dominant-negative mutant of I
B kinase
and troglitazone at 8 µmol/L, an activator of peroxisome proliferatoractivated receptor
, abolished the shear stressinduced increase in PRMT-1 gene expression in parallel with the blockade of nuclear factor (NF)-
B translocation into the nucleus. The activity of dimethylarginine dimethylaminohydrolase, the degradation enzyme of ADMA, was unchanged after shear stress
15 dyne/cm2 and was enhanced by 1.48±0.06-fold (P<0.05) by shear stress at 25 dyne/cm2. The release of ADMA was increased by 1.64±0.10-fold (P<0.05) by shear stress at 15 dyne/cm2 but was not affected by shear stress at 25 dyne/cm2. These results indicate that shear stress enhances gene expression of PRMT-1 and ADMA release via activation of the NF-
B pathway. Shear stress at higher magnitudes facilitates the degradation of ADMA, thus returning ADMA release levels to baseline.
Key Words: stress, mechanical endothelium gene expression arginine nitric oxide nitric oxide synthase
This article has been cited by other articles:
![]() |
P. P. Landburg, T. Teerlink, E. J. van Beers, F. A.J. Muskiet, M. C. Kappers-Klunne, J. W.J. van Esser, M. R. Mac Gillavry, B. J. Biemond, D. P.M. Brandjes, A. J. Duits, et al. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension Haematologica, September 1, 2008; 93(9): 1410 - 1412. [Full Text] [PDF] |
||||
![]() |
C. Baylis Nitric oxide deficiency in chronic kidney disease Am J Physiol Renal Physiol, January 1, 2008; 294(1): F1 - F9. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fang, J.-J. Mu, L.-C. He, S.-C. Wang, and Z.-Q. Liu Salt Loading on Plasma Asymmetrical Dimethylarginine and the Protective Role of Potassium Supplement in Normotensive Salt-Sensitive Asians Hypertension, October 1, 2006; 48(4): 724 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Perticone, A. Sciacqua, R. Maio, M. Perticone, R. Maas, R. H. Boger, G. Tripepi, G. Sesti, and C. Zoccali Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension J. Am. Coll. Cardiol., August 2, 2005; 46(3): 518 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, July 1, 2005; 10(1_suppl): S49 - S57. [Abstract] [PDF] |
||||
![]() |
H. Tomita, T. Osanai, T. Toki, S. Sasaki, N. Maeda, R. Murakami, K. Magota, M. Yasujima, and K. Okumura Troglitazone and 15-deoxy-{Delta}12,14-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells Cardiovasc Res, July 1, 2005; 67(1): 134 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrera and J. L. Garvin Recent Advances in the Regulation of Nitric Oxide in the Kidney Hypertension, June 1, 2005; 45(6): 1062 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maas Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA) Vascular Medicine, May 1, 2005; 10(2_suppl): S49 - S57. [Abstract] [PDF] |
||||
![]() |
R. J. Nijveldt, M. P. C. Siroen, T. Teerlink, and P. A. M. van Leeuwen Elimination of Asymmetric Dimethylarginine by the Kidney and the Liver: A Link to the Development of Multiple Organ Failure? J. Nutr., October 1, 2004; 134(10): 2848S - 2852S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vallance and J. Leiper Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1023 - 1030. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |